In our previous clinical study of treatment of subjects with overweight and obesity with tRES + HESP, the pharmacological target validation of the Nrf2-dependent induction of increased Glo1 expression and activity was achieved [39]. The gene discussed is GLO1; the disease is obesity due to melanocortin 4 receptor deficiency.